- Home
- ABLV vs RNXT Comparison
ABLV vs RNXT Comparison
Compare ABLV & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | RNXT |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | China | United States |
| Employees | 164 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 37.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABLV | RNXT |
|---|---|---|
| Price | $1.00 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 96.1K | ★ 290.1K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $0.54 | $0.70 |
| 52 Week High | $1.77 | $1.45 |
Technical Indicators
Market Signals| Indicator | ABLV | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 64.21 | 37.95 |
| Support Level | $0.82 | $0.70 |
| Resistance Level | $1.08 | $1.07 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 83.81 | 19.56 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.